Rocket Lab's $1.94 Billion Share Plan Puts the Iridium Deal in the Spotlight

Institutional investors buy Rocket Lab dip as Iridium acquisition nears, but $1.94B equity program raises dilution fears despite strong operations.

Institutional investors are quietly buying the dip in Rocket Lab even as the stock trades deep below its recent averages, with the company's largest-ever acquisition and a fresh equity program colliding in a defining moment for the space contractor.

IEQ Capital LLC disclosed a $2.59 million purchase of Rocket Lab shares in a regulatory filing that became public on Monday, joining Allworth Financial LP, which has also opened a new position in the stock. The buys arrive as the shares sit roughly 18 percent beneath their 50-day moving average of €70.02, a stretch of weakness that began when expectations for a Neutron debut this year were walked back.

The Iridium Deal and the Dilution Question

The centerpiece of Rocket Lab's near-term strategy is its planned takeover of Iridium Communications, and the regulatory machinery is now grinding forward. The antitrust waiting period expired on August 12, one day after the company filed its S-4 registration statement with the SEC, while license-transfer applications were simultaneously submitted to the FCC.

What makes the transaction particularly consequential for existing shareholders is how it will be funded. On August 13, Rocket Lab entered into a new equity distribution agreement with Deutsche Bank Securities and Wells Fargo Securities, permitting the sale of shares worth up to $1,944,369,826. The program replaces the previous one, and no additional shares will be issued beyond what remained unplaced under that earlier arrangement.

The sheer size of the program signals that fresh equity will likely finance a meaningful chunk of the Iridium purchase, raising the specter of dilution that the market appears to be pricing in. Whether the strategic logic of folding Iridium's global satellite constellation into Rocket Lab's vertically integrated space ambitions justifies that cost remains the open question.

Operations Keep Delivering

While the financing debate simmers, the day-to-day business has not missed a beat. The 93rd Electron mission lifted off on August 20 from New Zealand carrying an iQPS radar Earth-observation satellite — the 14th launch of 2026 and the ninth for that customer, with nine more firmly booked Electron flights for iQPS stretching to 2030.

Days earlier, on August 15, eight satellite platforms built by Rocket Lab for MDA Space reached orbit, the first tranche of 17 under a $143 million contract supporting Globalstar's direct-to-device services. The cadence is unspectacular but dependable — exactly the kind of operational continuity that builds investor trust.

The financials reinforce that picture. Rocket Lab posted record second-quarter revenue of $234 million and a backlog of $2.36 billion, with management pointing to more than a billion dollars in new contracts secured during and after the quarter.

Neutron Remains the Wild Card

The launch vehicle that is supposed to power the next phase of growth remains the biggest source of uncertainty. Bloomberg reported roughly two weeks ago that Rocket Lab is tempering expectations for a first flight this year, and the company reiterated a target of delivering Neutron to the pad in the fourth quarter of 2026 — a deadline whose fate will likely shape investor confidence more than any single mission success.

That timing question, layered on top of the dilution debate, explains the share price trajectory. The stock traded at €57.50 on Tuesday, down 11 percent over seven days, even as it remains 39 percent higher on a year-to-date basis. The longer-term growth narrative is evidently still intact for many holders, but near-term nerves are winning the day.

For investors weighing the conflicting signals, the calculus comes down to whether the operational momentum — the iQPS series, the MDA Space work, the swelling backlog — can eventually outweigh the twin overhangs of dilution risk and launch delays. The institutional buyers stepping in now are betting it can, though the next several months will be dominated less by routine mission successes than by financing details and the Neutron timeline.